SNOOP COMMUNICATIONS

 Oba MacGregor Leads Chart To Fill Pharmaceutical Vacuum Through Sygen-ORx Partnership

In a bid to fill the vacuum left by pharmaceutical giants, a renowned inventor, world acclaimed pharmaceutical industrialist, Professor of  Biopharmaceutics and CEO of Canada’s Orx Pharmaceutical Corporation, His Royal Majesty Oba (Prof) Alexander Olusegun MacGregor is leading a scientifically-driven paradigm shift on how Africans access drugs manufactured by global pharmaceutical companies through a partnership with Sygen Pharmaceuticals Limited.

The joint venture with Sygen Pharmaceuticals Limited, the famous makers of ABIDEC Multivitamin Drops was sealed early this year essentially to develop generic medicines tailored to the unique physiological needs of Nigerians and Africans.

The Sygen-ORx partnership combines the expertise of both companies to improve patient care and advanced medical science by modifying improved formulations of generic drugs that have received regulatory approvals and achieved substantial commercial success. 

By leveraging on Oba Macgregor's extensive experience as a pharmaceutical scientist and inventor with numerous ground-breaking inventions, the issue of fake and substandard drugs will be curbed even as the cost of these locally-made drugs will be greatly affordable.

Speaking on the Sygen-ORx partnership, Oba Macgregor who is also the Founder and President of the Toronto Institute of Pharmaceutical Technology (TIPT) Canada and the Olu of Orile Ilawo Egba land expressed his delight over the joint venture, describing it as historic.

In a recent television interview monitored on Arise News, the industrialist expressed his confidence at the success of the venture. According to him, "The venture is primed to provide the basic foundation for other parties in the pharmaceutical  industry to develop the courage to enter into the Research & Development space. We are coming from a wealth of experience; we know exactly how it is done; we know what to be done and we know how to remodel what we are doing to suit our environment," says the Ilawo monarch.

He continued: "The joint venture will improve on the output of people in the continent in terms of drug outcome in the efficacy of drugs a

nd how drugs perform in our system.

Oba MacGregor added: "Sygen ORx partnership is going to be at the frontier of the pharmaceutical sector in terms of innovation and bringing new drugs to Nigeria. Drugs that are not existing already and some drugs that are existing but are being repurposed. Repurpose mean two things. First, finding a useful existing drug that doesn't exist and modifying existing drugs to work better.

I can see this partnership really changing the dynamics of the way Nigerians receive drugs rather than dependent on imported drugs that we don't know much about how they develop them but we buy them anyway. So many of them don't work but we consume them a lot. So, we start by focusing on inwards," he added  

Part of the strategies for looking inwards according to the renowned professor is for collateral industries to flourish. "Collateral industries will develop. For example, pharmaceutical ingredient manufacturing companies can grow cassava for pharma use which must be made at a higher level of purity hence that industry will blossom," he concluded